Press Release: Xenpozymetm (Olipudase Alfa-Rpcp) Approved By FDA As First Disease-Specific Treatment For ASMD (Non-CNS Manifestations)

Press/Media

Period	31 Aug 2022

Media coverage

Title	Press Release: Xenpozymetm (Olipudase Alfa-Rpcp) Approved By FDA As First Disease-Specific Treatment For ASMD (Non-CNS Manifestations)
Media name/outlet	MENAFN -Press Releases (English)
Country/Territory	Jordan
Date	31/08/22
URL	metabase.moreover.com/noarticleurl?type=psh&lni=66R3-5351-DY6B-21M0-00000-00
Persons	Melissa Wasserstein